Open an account

Intellia Therapeutics

NTLA · NASDAQ

$11.84+$0.26 (+2.25%)TodayMarket closed ·
Prev close $11.58

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 377 full-time employees. The company went IPO on 2016-05-06. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The firm is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.

Employees
377
Headquarters
Cambridge, Massachusetts
Listed
May 6, 2016
Sector
Health Care
Industry
Biotechnology
Website
intelliatx.com

NTLA key statistics

Market cap
1.66B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.97M
Volume
3.42M
Open price
$11.43
High today
$12.00
Low today
$11.28
52 Week high
$28.25
52 Week low
$7.95

Intellia Therapeutics (NTLA) at a glance

Intellia Therapeutics (NTLA) last traded at $11.84, with a market cap of 1.66B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.28 and $12.00. The current price is 4.9% above the day's low and 1.3% below its high.

Volume so far is 3.42M shares, below the average of 5.97M shares a day.

Over the past year Intellia Therapeutics has ranged from $7.95 to $28.25, and now sits 19% of the way up that range.

The average analyst price target is $25.36, 114.2% above the current price, from 21 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

52%of 21 analyst ratings say Buy
  • Buy52.4%
  • Hold28.6%
  • Sell19.0%
Price target · 18 analystsAvg $25.36
Low
$9.09
Now
$11.84
High
$64.05

NTLA news

  • Chandrima Sanyal

    Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up

  • Chandrima Sanyal

    Cathie Wood Trims 40K Shopify Shares After August Rally: Where ARK Is Reinvesting?

  • Press releaseGlobe Newswire

    Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

  • Vandana Singh

    Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

  • Erica Kollmann

    Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze (CORRECTED)

  • Vandana Singh

    Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

  • Press releaseGlobe Newswire

    Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Intellia Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.